Galmed Pharmaceuticals Ltd

NASDAQ:GLMD  
1.60
-0.03 (-1.84%)
Products

Galmed Announces Positive Results Of Phase 1 Study Of AMILO-5MER

Published: 01/10/2022 12:45 GMT
Galmed Pharmaceuticals Ltd (GLMD) - Galmed Announces Positive Results of Phase 1 Study of Amilo-5mer.
Galmed Pharmaceuticals Ltd - Single and Multiple Escalating Dose Results With Excellent Safety Profile and Tolerability.
Galmed Pharmaceuticals Ltd - Submission of an Ind for Mild to Moderate Ulcerative Colitis is Planned in 2022.
Galmed Pharmaceuticals Ltd - All Doses of Amilo-5mer Were Well Tolerated With No Clinically Significant Adverse Events.